≡ Risteys
R9

Documentation Changelog GitHub Contact & Feedback

Ovarian dysfunction: androgen excess, drug-induced

PheWeb

E4_ODANDRO_ADVERSE

No definition available.

Endpoint definition

↥
FinnGen phenotype data

392423 individuals

diagram downward connector
diagram bullet

Apply sex-specific rule

Sex only females

219462

diagram downward connector

Check conditions None

219462

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital discharge: ATC codes for adverse effects of drugs ANY
Hospital Discharge: ICD-10 E28.1#

1 out of 7 registries used, show all original rules.

5

diagram downward connector

Check minimum number of events None

5

diagram downward connector

Include endpoints None

5

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

-

diagram downward connector
E4_ODANDRO_ADVERSE

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy C
First used in FinnGen datafreeze DF5
Parent code in ICD-10 E28
Name in latin Hypersecretio androgenorum

Not enough data for upset plot.

Or the full data table

Similar endpoints

↥

List of similar endpoints to Ovarian dysfunction: androgen excess, drug-induced based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

None

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

All Female Male
Number of individuals - - -
Unadjusted prevalence (%) - - -
Mean age at first event (years) - - -

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: E4_ODANDRO_ADVERSE – Ovarian dysfunction: androgen excess, drug-induced
GWS hits:

Survival analyses between endpoints

↥

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Ovarian dysfunction: androgen excess, drug-induced

↥

Endpoint not on priority list, no data to show.